Aflac Incorporated sells supplemental health and life insurance through businesses in Japan and the United States. Its news commonly covers earnings from Aflac Japan and Aflac U.S., sales trends in medical, cancer, life, accident, dental, vision, disability and long-term care products, and capital actions such as dividends and share repurchases.
Company updates also address worksite and group benefits, absence and paid-leave administration, reinsurance activity through Aflac Re Bermuda, and health-related initiatives tied to cancer screening and patient support. Product announcements in Japan include Anshin Palette medical insurance, Miraito cancer insurance and Tsumitasu life insurance, while U.S. updates focus on group voluntary benefits, network dental and vision, group life, disability and long-term care riders.
Aflac's My Special Aflac Duck(R) has been proven effective in helping children cope with cancer, as shown in recent clinical research. The robotic duck reduces distress, nausea, pain, and anxiety associated with cancer treatments, benefiting both pediatric cancer patients and caregivers. The unexpected positive findings from the study highlight the valuable contribution of the duck in supporting the entire children's ecosystem. More than 29,000 ducks have been distributed free of charge to children diagnosed with cancer and blood disorders, showcasing Aflac's commitment to children's health.
Aflac Incorporated reported strong first-quarter results with total revenues of $5.4 billion, net earnings of $1.9 billion, and a second-quarter cash dividend declared. Shareholders' equity increased to $23.5 billion with a return on equity of 33.0%. Aflac Japan saw net earned premiums decline in yen terms but increased profit margins. Aflac U.S. experienced growth in net earned premiums and adjusted net investment income. The board declared a dividend of $0.50 per share and $750 million was deployed to repurchase shares.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.